Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma and the European Myeloma Network. Ozaki S et al. Acta Haematol. 2014 Mar 22;132(2):211-219. [Epub ahead of print]. Pathways for blood and bowel cancer patients…
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK et al. Biol Blood Marrow Transplant. 2014 Mar 6. pii: S1083-8791(14)00148-7. doi: 10.1016/j.bbmt.2014.02.025. [Epub ahead of print].
Plasma Exchange for Kidney Disease: What Is the Best Evidence?
Hildebrand AM et al. Adv Chronic Kidney Dis. 2014 Mar;21(2):217-227. doi: 10.1053/j.ackd.2014.01.008.
Rapid Progression of Anemia Related to Tumor-lysis Syndrome Associated with Bortezomib Treatment in Myeloma Patients. Suzuki K et al. Jpn J Clin Oncol. 2014 Mar 23. [Epub ahead of print]. Prediction of presence of kidney disease in a general patient population undergoing intravenous iodinated contrast enhanced computed tomography. Moos SI et al. Eur Radiol. 2014…
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.Fouquet G et al. J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.Mark TM et al. Leuk Lymphoma. 2014 Mar 25. [Epub ahead of…
The Pharmacokinetics and Pharmacodynamics of Denosumab in Patients with Advanced Solid Tumours and Bone Metastases: A Systematic Review. Sohn W et al. Br J Clin Pharmacol. 2014 Feb 18. doi: 10.1111/bcp.12355. [Epub ahead of print]. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective…
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Dimopoulos MA et al. Leukemia. 2014 Feb 5. doi: 10.1038/leu.2014.60. [Epub ahead of print]. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Engelhardt M et al. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.…
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Palumbo A et al. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(13)70609-0. doi: 10.1016/S1470-2045(13)70609-0. [Epub ahead of print]. Lenalidomide and second malignancies in myeloma patients. Pratt G. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(14)70001-4. doi: 10.1016/S1470-2045(14)70001-4. [Epub ahead of print].…
Subcutaneous Bortezomib incorporated into the Bortezomib-Thalidomide-Dexamethasone regimen as part of frontline therapy in the context of autologous stem-cell transplantation for multiple myeloma.
Lok A et al. Haematologica. 2014 Feb 14. [Epub ahead of print]
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Palumbo A et al. J Clin Oncol. 2014 Jan 13. [Epub ahead of print]. Initial treatment of transplant-eligible patients in multiple myeloma. Rosiñol L et al. Expert Rev Hematol. 2014 Jan…
Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure.Wohlfarth P et al. Crit Care. 2014 Jan 20;18(1):R20. [Epub ahead of print].Clearance of Drugs for Multiple Myeloma Therapy During In Vitro High-Cutoff Hemodialysis.Krieter DH et al. Artif Organs. 2014 Jan 7. doi: 10.1111/aor.12248. [Epub ahead of print].Acupuncture for neuropathic pain due…